Skip to main content

Sampo plc’s share buybacks week 26/2026

Sampo plc, stock exchange release, 29 June 2026 at 8:30 am EEST Sampo plc’s share buybacks week 26/2026 During week 26 (22 June 2026 – 26 June 2026), Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:Market (MIC Code) Daily volume (in number of shares) and weighted average price of the purchased shares, EUR* Aggregated weekly volume (in number of shares) and weighted weekly average price of the purchased shares, EUR*    22/06/2026 23/06/2026 24/06/2026 25/06/2026 26/06/2026 Week 26/2026, totalAQEU Volume 1,464 82,914 3,150 – 4,183 91,711Average price 9.15 8.91 8.93 – 9.01 8.92CEUX Volume 161,985 547,780 125,802 – 68,080 903,647Average price 9.11 8.90 8.93 – 9.02 8.95TQEX Volume 51,419 56,506 27,220 – 15,700 150,845Average...

Continue reading

Bavarian Nordic Receives Health Canada Approval for Chikungunya Vaccine

COPENHAGEN, Denmark, June 29, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Health Canada has approved VIMKUNYA® (recombinant, adsorbed) for immunization to prevent disease caused by chikungunya virus infection for individuals 12 years of age and older. The single-dose vaccine is the first virus-like particle (VLP) vaccine approved in Canada for protection against the mosquito-borne chikungunya virus, expanding preventive options for travelers to endemic and outbreak regions. This marks the fifth regulatory approval of VIMKUNYA, which has also been approved by the U.S. Food and Drug Administration (FDA), the European Commission, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and Swissmedic. Paul Chaplin, President and CEO of Bavarian Nordic, said: “Health Canada’s approval marks an important milestone in...

Continue reading

SBM Offshore completes US$465 million financing of FSO Chalchi

Amsterdam, June 29, 2026 SBM Offshore announces it has signed the project financing of FSO Chalchi for a total amount of US$465 million. The project financing is provided by a consortium of international banks and institutional investors and includes partial insurance cover from China Export & Credit Insurance Corporation. The project financing will be drawn during the construction period and will become non-recourse after the FSO has started operations. The loans have a maximum tenor of c. 14 years post completion. FSO Chalchi is currently under construction and will be operated under 20-year lease and operate contracts with Woodside Energy through its affiliate in Mexico, Woodside Petróleo Operaciones de México, S. de R.L. de C.V. (Woodside). The new build FSO is based on a Suezmax-type hull and will be equipped with a Disconnectable...

Continue reading

Share repurchase programme: Transactions of week 26 2026

The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 1,288,703 905.98 1,167,536,62722 June 2026 12,275 956.84 11,745,24323 June 2026 12,419 948.10 11,774,49124 June 2026 12,471 937.02 11,685,56425...

Continue reading

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications. Powered by innovative SBX technology, the platform is capable of end-to-end, same-day whole-genome sequencing in research workflows, with accurate results within hours. The AXELIOS 1 platform holds promise for research laboratories today, and potentially for a broad range of clinical settings in the future.Basel, 29 June 2026 — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scalability and cost efficiency that addresses critical bottlenecks in genomics and potentially in clinical research. AXELIOS 1 will...

Continue reading

Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline

Acquisition adds navtemadlin, a late-stage rare blood cancer asset in Phase III. This hemato-oncology program in myelofibrosis expands Ipsen’s growing Oncology portfolio Navtemadlin, an oral MDM2 inhibitor, has the potential, through disease modifying activity, to transform suboptimal responses to standard of care ruxolitinib into clinically meaningful responses in patients with myelofibrosis Top-line data from the ongoing Phase III registrational trial POIESIS is expected in 2027PARIS, FRANCE AND REDWOOD CITY, U.S., 29 JUNE 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) and Kartos Therapeutics, announced today they have entered into a definitive merger agreement under which Ipsen has agreed to acquire Kartos Therapeutics. The acquisition adds navtemadlin, an investigational MDM2 inhibitor designed to restore the natural tumor-suppressing...

Continue reading

WISeKey International Holding Ltd Signs Merger Agreement to Redomicile to the British Virgin Islands

WISeKey International Holding Ltd Signs Merger Agreement to Redomicile to the British Virgin Islands Zug, Switzerland, June 29, 2026 – Ad-Hoc announcement pursuant to Art. 53 of SIX Listing Rules – WISeKey International Holding AG (“WISeKey”) (SIX: WIHN; Nasdaq: WKEY) today announced that it has signed a merger agreement with WISeKey International Corp., a British Virgin Islands company and wholly owned subsidiary of WISeKey (“WISeKey BVI”), to effect WISeKey’s proposed redomiciliation from Switzerland to the British Virgin Islands. Under the proposed transaction, WISeKey would merge with and into WISeKey BVI, with WISeKey BVI surviving the merger as the publicly traded parent company of the WISeKey group and successor to WISeKey. Following completion of the redomiciliation, WISeKey BVI is expected to have its ordinary shares directly...

Continue reading

Turing Award Laureate Joseph Sifakis Appointed Chief Scientific Advisor as CaoCao Accelerates AI Transformation

HANGZHOU, China, June 29, 2026 (GLOBE NEWSWIRE) — On June 29, Joseph Sifakis, a world-renowned AI scientist and Turing Award laureate, was formally invited to serve as Chief Scientific Advisor of the CaoCao AI Innovation Center. He will provide core academic support, a global perspective and strategic roadmap guidance for CaoCao’s transformation into an AI-native company. Professor Sifakis is one of the leading pioneers in trustworthy artificial intelligence and complex systems. He has long focused on the safety, reliability and verifiability of complex intelligent systems, with his research widely applied in safety-critical fields such as aerospace and industrial control. In recent years, Professor Sifakis has concentrated on trustworthy AI and autonomous systems. His research aligns closely with the development needs of Robotaxi...

Continue reading

OPPOLIA Launches AI-Powered Factory to Expand Global Reach

OPPOLIA AI FactoryOPPOLIA AI FactoryDUBAI, United Arab Emirates, June 29, 2026 (GLOBE NEWSWIRE) — OPPOLIA Home, a subsidiary of OPPEIN Home Group Inc. – the world’s leading custom cabinetry manufacturer, has officially put into operation its latest intelligent manufacturing facility, integrating advanced automated processing and AI-driven technologies. Founded in 2015, OPPOLIA is a leading player in the Asian custom home furnishings market. The company offers a wide range of products, including custom cabinetry, furniture, doors, and windows, to deliver a comprehensive furnishing solution for families around the world. To sustain steady growth in production capacity and efficiency, the company has poured over USD 140 million into R&D and technological innovation. This investment has laid the groundwork...

Continue reading

HP Inc. Launches Frontier Strategic Partnership with OpenAI to Fuel Customer-Facing Experiences and Transform Internal Operations

News Highlights: HP Inc. will deploy powerful AI-driven solutions with OpenAI Frontier to help drive HP transformation and growth initiatives  The Frontier platform will be used across HP’s business, to enhance customer-facing experiences and internal operations   The Frontier strategic partnership supports HP’s efforts to deliver an advanced telemetry platform with WXP, a recognized Gartner magic quadrant leader, enabling a connected device layer for the AI era PALO ALTO, Calif., June 28, 2026 (GLOBE NEWSWIRE) — Today, HP Inc. (NYSE: HPQ) announced the launch of a strategic partnership with OpenAI, integrating its Frontier platform into HP’s global efforts to shape the Future of Work through enhanced customer-facing experiences and accelerated transformation across its operations.   “With OpenAI there is an opportunity to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.